ELLEX MEDICAL LASERS LTD (ASX:ELX)
Presentation to Annual General Meeting
Adelaide, Australia
28 November 2017
Disclaimer

This presentation has been prepared by Ellex Medical Lasers Ltd (Ellex). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward-looking statements have been made based upon Ellex’s expectations and beliefs concerning future developments and their potential effect on Ellex (and it’s controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Ellex’s control. No assurance is given that future developments will be in accordance with Ellex’s expectations. Actual results could differ materially from those expected by Ellex. This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.
Presentation to 2017 Annual General Meeting

1. Our Opportunity
2. Our Strategy
3. Our Progress, Fiscal Year 2017
4. Our Outlook, Fiscal Year 2018
Targeting a Large and Growing Market

- **82m** people worldwide with glaucoma
  - **Glaucoma** US $4.6bn
  - Global market size: US $4.6bn

- **107m** people worldwide with diabetic retinal disease
  - **Retinal Disease** US $1.9bn
  - Global market size: US $1.9bn

- **122m** people with early age-related macular degeneration
  - **Early AMD** US $5.1bn
  - Yearly operations: 25.3m

- **25.3m** cataract operations performed per year
  - **Cataract** US $3.3bn
  - Global market size: US $3.3bn

- Ellex has the brand, distribution channels, products and product pipeline to exploit this opportunity
- Glaucoma segment accessible to Ellex expected to grow from US$285m pa to US$1.4bn pa by 2022

---

Ellex is Structured around Three Business Streams Tied to the Opportunities

1. **Current Stream** – Ellex Core Laser and Ultrasound business delivering stable revenue and earnings

2. **The Next Stream** – Ellex iTrack with SLT for the emerging drug-free glaucoma therapy that is building significant momentum

3. **The Future Stream** – The treatment of early stage age-related macular degeneration with 2RT undergoing multicentre clinical trial to show efficacy
Ellex Core Laser & Ultrasound

- Ellex core business of laser & ultrasound products used by ophthalmologists worldwide has achieved revenue growth CAGR of 8% over FY2013 to FY2017. This exceeds industry growth rates.\(^{(1)}\)

\(^{(1)}\) The market growth rate estimated by MarketScope “2017 Ophthalmic Lasers Report”
Ellex iTrack™
A MIGS Device that Treats Glaucoma

• The Ellex iTrack™ is a unique, patent-protected microcatheter for treating patients with mid stage glaucoma used to clear and flush the main ocular drainage systems to restore natural biology
• Perfect compliment to Ellex SLT
• Can be repeated and revitalises natural outflow pathways, leaving nothing behind (US competitors stents)
• Current market accessible for MIGS and canaloplasty devices US$240 million p.a. growing to US$1.4bn p.a. by 2022 (44% CAGR)¹

¹ MarketScope “2017 Glaucoma Surgical Devices Report”
2RT® for Early AMD
Ellex 2RT® - Potentially Game-changing Interventional Treatment for Early to Intermediate AMD

- Substantial growth opportunity pending results of clinical trial.
- Unique, patent-protected nano pulse laser that rejuvenates aging retinal cells, thus delaying progression to late stage AMD.
- Sales to early adopters taking place under CE mark. Ellex has in-place distribution channel to roll Ellex 2RT® out.
Ellex Core Laser & Ultrasound Progress in FY17

- The core laser and ultrasound business provides products used everyday by ophthalmologists globally.
- World-leading positions in cataracts and glaucoma lasers.
- CAGR for revenue FY13 to FY17 is 8%.
- Ellex has a dominant position in SLT lasers for glaucoma. Recently released and patented “Reflex” technology is expected to drive further growth in market share.
- Ellex also has a significant market positions in diagnostic ocular ultrasound and retinal lasers.
• Core laser and ultrasound profitability relatively stable

• Average fully-burdened gross margin percentage greater than 50%
Ellex Core Laser & Ultrasound: Manufacturing Upgrade

- Expanded production footprint to 7,400sqm with increased cleanrooms capacity and precision machine shop capability
- Move project took place over August 2016 to March 2017 including site qualification audit by Australian Therapeutic Goods Administration (TGA)
Ellex iTrack™
Progress in FY2017 and Q1 FY2018

- Sales growth in FY17H2 accelerated due to expansion of USA sales team and improvement in reimbursement effective 1 January 2017 (71% growth in FY18 Q1 in USA and globally)
- Good growth in markets outside the US and sales into China
- Reported sales for the year to 30 June 2017 of A$8.2m
- Acceleration of annual revenue to 46% above June 2016 annual revenue rate
- USA sales force recruitment, additional marketing, reimbursement increase on 1 January 2017
Ellex iTrack™
Progress in FY2017 and Q1 FY2018

<table>
<thead>
<tr>
<th></th>
<th>FY16</th>
<th>FY17 Reported</th>
<th>FY18 Q1</th>
<th>Growth % Q1FY18</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>3.9</td>
<td>4.7</td>
<td>1.2</td>
<td>+71</td>
</tr>
<tr>
<td>Asia</td>
<td>0.3</td>
<td>1.0</td>
<td>0.2</td>
<td>&gt;100%</td>
</tr>
<tr>
<td>Rest of World</td>
<td>2.2</td>
<td>2.5</td>
<td>0.6</td>
<td>+36%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>6.3</strong></td>
<td><strong>8.2</strong></td>
<td><strong>2.0</strong></td>
<td><strong>+71%</strong></td>
</tr>
</tbody>
</table>
Ellex iTrack™ USA Sales: Five Quarters of Growth

USA iTrack™ Sales by Quarter in US$'000's

USA growth on Q1FY17

USA growth on Q1FY17
2018 Outlook:
Strategy and the Recent Capital Raise

- $23.2m raised on 2 November from Australian and US institutions to access this significant opportunity
- The additional funds are being used for:
  - Expansion of sales and marketing of Ellex iTrack™ in the USA and in strategic markets outside the USA
  - Production capacity expansion and product development for Ellex iTrack™
  - Improved marketing and clinical training in the core laser and ultrasound business
2018 Outlook: Strategy and the Recent Capital Raise (cont’d)

• As a result of the cash flow from the core laser and ultrasound business, combined with the recent capital raise, Ellex is now well capitalised to execute its growth strategy.
Sales within the Core Laser and Ultrasound business through to 31 October 2017 are 2% above sales for the same period in FY17 after allowing for the appreciation of the Australian dollar against the YEN, Euro and US$.

Ellex lasers for treating glaucoma and for treating vitreous opacities continue to perform well in the market.

Sales for Ellex iTrack for the three months to 30 September, 2017 grew 71% (in US$) in the USA on the prior corresponding period. During the month of October 2017 this sales growth rate accelerated.

The recent capital raise provides the opportunity to invest in sales team expansion, marketing (KOL engagement, symposia, journal production, studies, wetlab roadshows, international approvals and reimbursement and tradeshow attendance) and production infrastructure at Fremont across FY18 and FY19 in order to further increase the sales growth rate.
For further information on Ellex Medical Lasers please contact:

Tom Spurling  
CEO  
m: +61 417 818 658  
e: tspurling@ellex.com

Maria Maieli  
CFO & Company Secretary  
w: +61 8 7074 8200  
e: mmaielie@ellex.com

Andrew Angus  
Investor Relations  
w: +61 402 823 757  
e: andrewangus@overlandadvisers.com.au
THANK YOU